#United States #Atlanta #Neurelis #CCM #NRL-1049

Neurelis at the Annual CCM Meeting: Focus on NRL-1049

Neurelis, Inc., a leading player in neuroscience innovation, has announced its participation in the upcoming Alliance to Cure Cavernous Malformation (CCM) 21st International Scientific Meeting scheduled for November 6-7, 2025, in Atlanta, Georgia. This year marks a significant occasion for the company as it will present crucial findings from its Phase 1 clinical study on NRL-1049, a promising Rho kinase (ROCK) inhibitor.

Understanding CCM and NRL-1049

Cerebral Cavernous Malformations (CCM) represent a rare but serious neurovascular disorder affecting about 1 in every 500 individuals. This condition manifests through clusters of enlarged and fragile blood vessels in the brain and spinal cord, which heightens the risk of leakage and hemorrhage. Symptoms can vary widely, including headaches, neurological deficits, and even seizures, which significantly affect patients' quality of life.

The Phase 1 study focuses on the pharmacokinetics and safety of NRL-1049, showcasing data that reflects a straightforward dose-proportional increase in exposure, alongside a favorable safety profile. The study identified a maximum tolerated dose of 150 mg, suggesting NRL-1049’s potential as a therapeutic option for managing CCM.

A Platform for Collaboration

Dr. Adrian L. Rabinowicz, Chief Medical Officer at Neurelis, emphasized the importance of the CCM meeting, a forum where researchers, clinicians, and patients converge to discuss the latest advancements in treatment strategies for this debilitating condition. "This year's meeting holds a special significance as it is our first opportunity to share data with the CCM community. We are eager to engage and collaborate towards finding better treatment options for those affected by CCM," stated Dr. Rabinowicz.

The likelihood of cerebral hemorrhage is a major concern for CCM patients, with the probability increasing with successive hemorrhagic events, heightening risk for morbidity and mortality. Current approaches to manage CCM are limited, making Neurelis’s research particularly relevant and critical.

The Poster Presentation

On November 6, from 4-5:30 PM ET, Neurelis will hold a poster presentation titled, A Phase 1, First-in-Human, Single-Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of a ROCK Inhibitor (NRL-1049) in Healthy Volunteers. This session will illustrate the study's findings and clinical data derived from healthy adult participants who received the NRL-1049 treatment.

Commitment to Neuroscience and Beyond

Neurelis remains at the forefront of neuroscience innovation, also being recognized for its other product, VALTOCO® (diazepam nasal spray), approved by the FDA for managing acute seizure episodes in both adults and children. This showcases the company's broader commitment to addressing unmet needs in neurological health while striving to enhance therapeutic interventions for conditions like CCM.

As Neurelis prepares for the upcoming meeting, it beckons hope not only for researchers and healthcare professionals but also for the patients and families currently battling the challenges posed by CCM. The engagement at the meeting will surely fuel further research and collaborative efforts that could lead to significant advancements in how this rare malformation is treated and managed.

To stay updated on Neurelis’s latest findings and innovations in neuroscience, please visit www.neurelis.com.